ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2019-1-119-130ssmu-2176Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESАллельные варианты генов человека, затрагивающие внутриклеточный жизненный цикл ВИЧ и регулирующие иммунный ответ на ВИЧ-инфекциюAllelic variants of human genes affecting HIV intracellular life cycle and regulating immune response to HIV infectionhttps://orcid.org/0000-0003-3064-8871ХаитовР. М.KhaitovR. M.

Хаитов Рахим Мусаевич, доктор медицинских наук, профессор, академик РАН, научный руководитель Института иммунологии

115478, г. Москва, Каширское шоссе, 24

Khaitov Rahim M., DM, Professor, Academician of the RAS, Scientific Director of the Institute of Immunology

24, Kashirskoye Sh., Moscow, 115478

https://orcid.org/0000-0003-0432-9439АлексеевЛ. П.AlexeevL. P.

Алексеев Леонид Петрович, доктор медицинских наук, профессор, член-корреспондент РАН, заведующий отделом, Институт иммунологии

115478, г. Москва, Каширское шоссе, 24

Alekseev Leonid P., DM, Professor, Corresponding Мember of the RAS, Head of the Department, Institute of Immunology

24, Kashirskoye Sh., Moscow, 115478

https://orcid.org/0000-0003-2864-6949ГудимаГ. О.GudimaG. O.

Гудима Георгий Олегович, доктор биологических наук, заведующий лабораторией

115478, г. Москва, Каширское шоссе, 24

Gudima Georgy O., DBSc, Head of the Laboratory, Institute of Immunology

24, Kashirskoye Sh., Moscow, 115478

goudima@mail.ruhttps://orcid.org/0000-0001-9280-8282КофиадиИ. А.KofiadiI. A.

Кофиади Илья Андреевич, доктор биологических наук, заведующий лабораторией

115478, г. Москва, Каширское шоссе, 24

Kofiadi Ilya A., DBSc, Head of the Laboratory

24, Kashirskoye Sh., Moscow, 115478

Институт иммунологииРоссияInstitute of ImmunologyRussian Federation201916052019181119130Copyright © Хаитов Р.М., Алексеев Л.П., Гудима Г.О., Кофиади И.А., 20192019Хаитов Р.М., Алексеев Л.П., Гудима Г.О., Кофиади И.А.Khaitov R.M., Alexeev L.P., Gudima G.O., Kofiadi I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/2176

В обзоре рассмотрены генетические факторы хозяина, влияющие на внутриклеточную часть жизненного цикла вируса иммунодефицита человека (ВИЧ), а также регулирующие ВИЧ-специфический иммунный ответ. К ним относятся гены, которые кодируют белки, обеспечивающие репликацию вируса и формирование новых вирионов; гены, кодирующие противовирусные защитные белки; гены HLA и ряд других. Варианты этих генов и их сочетания вносят вклад в устойчивость или чувствительность индивидуума к ВИЧ-инфекции, влияют на патогенез заболевания, а также связаны с эффективностью антиретровирусной терапии.

Host genetic factors influencing the intracellular part of HIV live cycle and regulating of HIV-specific immune response are reviewed. Its include genes coding proteins which support viral replication and assembly of new virions, genes coding antiviral defense proteins, HLA genes and some others. Variants of these genes and its compositions affect individual succeptibility/resistance to HIV infection, influence the pathogenesis of the disease and also associate with efficacy of antiretroviral therapy.

геныВИЧ-инфекцияиммунный ответантиретровирусная терапияgenesHIVimmune responseantiretroviral therapyReferencesFellay J., Ge D., Shianna K., Colombo S., Ledergerber B., Cirulli E., Urban T., Zhang K., Gumbs C., Smith J., Castagna A., Cozzi-Lepri A., De Luca A., Easterbrook P., Gьnthard H., Mallal S., Mussini C., Dalmau J., Martinez-Picado J., Miro J., Obel N., Wolinsky S., Martinson J., Detels R., Margolick J., Jacobson L., Descombes P., Antonarakis S., Beckmann J., O’Brien S., Letvin N., McMichael A., Haynes B., Carrington M., Feng S., Telenti A., Goldstein D. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 2009; 5 (12): e1000791. DOI: 10.1371/journal.pgen.1000791.Fellay J., Ge D., Shianna K., Colombo S., Ledergerber B., Cirulli E., Urban T., Zhang K., Gumbs C., Smith J., Castagna A., Cozzi-Lepri A., De Luca A., Easterbrook P., Gьnthard H., Mallal S., Mussini C., Dalmau J., Martinez-Picado J., Miro J., Obel N., Wolinsky S., Martinson J., Detels R., Margolick J., Jacobson L., Descombes P., Antonarakis S., Beckmann J., O’Brien S., Letvin N., McMichael A., Haynes B., Carrington M., Feng S., Telenti A., Goldstein D. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 2009; 5 (12): e1000791. DOI: 10.1371/journal.pgen.1000791.Konig R., Zhou Y., Elleder D., Diamond T., Bonamy G., Irelan J., Chiang C., Tu B., De Jesus P., Lilley C., Seidel S., Opaluch A., Caldwell J., Weitzman M., Kuhen K., Bandyopadhay S., Ideker T., Orth A., Miraglia L., Bushman F., Young J., Chanda S. Global analysis of hostpathogen interactions that regulate early-stage HIV-1 replication. Cell. 2008; 135 (1): 49–60. DOI: 10.1016/j.cell.2008.07.032.Konig R., Zhou Y., Elleder D., Diamond T., Bonamy G., Irelan J., Chiang C., Tu B., De Jesus P., Lilley C., Seidel S., Opaluch A., Caldwell J., Weitzman M., Kuhen K., Bandyopadhay S., Ideker T., Orth A., Miraglia L., Bushman F., Young J., Chanda S. Global analysis of hostpathogen interactions that regulate early-stage HIV-1 replication. Cell. 2008; 135 (1): 49–60. DOI: 10.1016/j.cell.2008.07.032.McLaren P., Carrington M. The impact of host genetic variation on infection with HIV-1. Nat. Immunol. 2015; 16 (6): 577–583. DOI: 10.1038/ni.3147.McLaren P., Carrington M. The impact of host genetic variation on infection with HIV-1. Nat. Immunol. 2015; 16 (6): 577–583. DOI: 10.1038/ni.3147.Хаитов Р.М. СПИД. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2018: 496.Khaitov R.M. AIDS. 2nd edition, revised and supplemented. Moscow: GEOTAR-Media Publ., 2018: 496 (in Russ.).Bashirova A., Bleiber G., Qi Y., Hutcheson H., Yamashita T., Johnson R., Cheng J., Alter G., Goedert J., Buchbinder S., Hoots K., Vlahov D., May M., Maldarelli F., Jacobson L., O’Brien S., Telenti A., Carrington M. Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J. Virol. 2006; 80 (14): 6757–6763. DOI: 10.1128/JVI.00094-06.Bashirova A., Bleiber G., Qi Y., Hutcheson H., Yamashita T., Johnson R., Cheng J., Alter G., Goedert J., Buchbinder S., Hoots K., Vlahov D., May M., Maldarelli F., Jacobson L., O’Brien S., Telenti A., Carrington M. Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J. Virol. 2006; 80 (14): 6757–6763. DOI: 10.1128/JVI.00094-06.Liu C., Perilla J., Ning J., Lu M., Hou G., Ramalho R., Himes B., Zhao G., Bedwell G., Byeon I., Ahn J., Gronenborn A., Prevelige P., Rousso I., Aiken C., Polenova T., Schulten K., Zhang P. Cyclophilin A stabilizes the HIV-1 capsid through a novel non-canonical binding site. Nat. Commun. 2016; 7: 10714. DOI: 10.1038/ncomms10714.Liu C., Perilla J., Ning J., Lu M., Hou G., Ramalho R., Himes B., Zhao G., Bedwell G., Byeon I., Ahn J., Gronenborn A., Prevelige P., Rousso I., Aiken C., Polenova T., Schulten K., Zhang P. Cyclophilin A stabilizes the HIV-1 capsid through a novel non-canonical binding site. Nat. Commun. 2016; 7: 10714. DOI: 10.1038/ncomms10714.Rits M., van Dort K., Kootstra N. Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection. PLoS One. 2008; 3 (12): e3975. DOI: 10.1371/journal.pone.0003975.Rits M., van Dort K., Kootstra N. Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection. PLoS One. 2008; 3 (12): e3975. DOI: 10.1371/journal.pone.0003975.Madlala P., Singh R., An P., Werner L., Mlisana K., Abdool Karim S., Winkler C., Ndung’u T. Association of polymorphisms in the regulatory region of the cyclophilin A gene (PPIA) with gene expression and HIV/AIDS disease progression. J. Acquir. Immune Defic. Syndr. 2016; 72 (5): 465–473. DOI: 10.1097/QAI.0000000000001028.Madlala P., Singh R., An P., Werner L., Mlisana K., Abdool Karim S., Winkler C., Ndung’u T. Association of polymorphisms in the regulatory region of the cyclophilin A gene (PPIA) with gene expression and HIV/AIDS disease progression. J. Acquir. Immune Defic. Syndr. 2016; 72 (5): 465–473. DOI: 10.1097/QAI.0000000000001028.Fribourgh J., Nguyen H., Wolfe L., Dewitt D., Zhang W., Yu X., Rhoades E., Xiong Y. Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase. J. Virol. 2014; 88 (6): 3309–3319. DOI: 10.1128/JVI.03824-13.Fribourgh J., Nguyen H., Wolfe L., Dewitt D., Zhang W., Yu X., Rhoades E., Xiong Y. Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase. J. Virol. 2014; 88 (6): 3309–3319. DOI: 10.1128/JVI.03824-13.Evans S., Schön A., Gao Q., Han X., Zhou X., Freire E., Yu X. HIV-1 Vif N-terminal motif is required for recruitment of Cul5 to suppress APOBEC3. Retrovirology. 2014; 11: 4–14. DOI: 10.1186/1742-4690-11-4.Evans S., Schön A., Gao Q., Han X., Zhou X., Freire E., Yu X. HIV-1 Vif N-terminal motif is required for recruitment of Cul5 to suppress APOBEC3. Retrovirology. 2014; 11: 4–14. DOI: 10.1186/1742-4690-11-4.An P., Duggal P., Wang L., O’Brien S., Donfield S., Goedert J., Phair J., Buchbinder S., Kirk G., Winkler C. Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet. 2007; 3 (1): e19. DOI: 10.1371/journal.pgen.0030019.An P., Duggal P., Wang L., O’Brien S., Donfield S., Goedert J., Phair J., Buchbinder S., Kirk G., Winkler C. Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet. 2007; 3 (1): e19. DOI: 10.1371/journal.pgen.0030019.Towers G. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology. 2007; 4: 40. DOI: 10.1186/1742-4690-4-40.Towers G. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology. 2007; 4: 40. DOI: 10.1186/1742-4690-4-40.Yamashita M., Emerman M. Cellular restriction targeting viral capsids perturbs human immunodeficiency virus type 1 infection of nondividing cells. J. Virol. 2009; 83 (19): 9835–9843. DOI: 10.1128/JVI.01084-09.Yamashita M., Emerman M. Cellular restriction targeting viral capsids perturbs human immunodeficiency virus type 1 infection of nondividing cells. J. Virol. 2009; 83 (19): 9835–9843. DOI: 10.1128/JVI.01084-09.van Manen D., Rits M., Beugeling C., van Dort K., Schuitemaker H., Kootstra N. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog. 2008; 4 (2): e18. DOI: 10.1371/journal.ppat.0040018.van Manen D., Rits M., Beugeling C., van Dort K., Schuitemaker H., Kootstra N. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog. 2008; 4 (2): e18. DOI: 10.1371/journal.ppat.0040018.Jaguva Vasudevan A., Smits S., Höppner A., Häussinger D., Koenig B., Münk C. Structural features of antiviral DNA cytidine deaminases. Biol Chem. 2013; 394 (11): 1357–1370. DOI: 10.1515/hsz-2013-0165.Jaguva Vasudevan A., Smits S., Höppner A., Häussinger D., Koenig B., Münk C. Structural features of antiviral DNA cytidine deaminases. Biol Chem. 2013; 394 (11): 1357–1370. DOI: 10.1515/hsz-2013-0165.Valcke H., Bernard N., Bruneau J., Alary M., Tsoukas C., Roger M. APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS. 2006; 20 (15): 1984–1986. DOI: 10.1097/01.aids.0000247124.35129.e1.Valcke H., Bernard N., Bruneau J., Alary M., Tsoukas C., Roger M. APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS. 2006; 20 (15): 1984–1986. DOI: 10.1097/01.aids.0000247124.35129.e1.An P., Johnson R., Phair J., Kirk G., Yu X., Donfield S., Buchbinder S., Goedert J., Winkler C. APOBEC3B Deletion and Risk of HIV-1 Acquisition. J. Infect. Dis. 2009; 200 (7): 1054–1058. DOI: 10.1086/605644.An P., Johnson R., Phair J., Kirk G., Yu X., Donfield S., Buchbinder S., Goedert J., Winkler C. APOBEC3B Deletion and Risk of HIV-1 Acquisition. J. Infect. Dis. 2009; 200 (7): 1054–1058. DOI: 10.1086/605644.Naruse T., Sakurai D., Ohtani H., Sharma G., Sharma S., Vajpayee M., Mehra N., Kaur G., Kimura A. APOBEC3H polymorphisms and susceptibility to HIV-1 infection in an Indian population. J. Hum. Genet. 2016; 61 (3): 263–265. DOI: 10.1038/jhg.2015.136.Naruse T., Sakurai D., Ohtani H., Sharma G., Sharma S., Vajpayee M., Mehra N., Kaur G., Kimura A. APOBEC3H polymorphisms and susceptibility to HIV-1 infection in an Indian population. J. Hum. Genet. 2016; 61 (3): 263–265. DOI: 10.1038/jhg.2015.136.An P., Penugonda S., Thorball C., Bartha I., Goedert J., Donfield S., Buchbinder S., Binns-Roemer E., Kirk G., Zhang W., Fellay J., Yu X., Winkler C. Role of APOBEC3F gene variation in HIV-1 disease Progression and Pneumocystis pneumonia. PLoS Genet. 2016; 12 (3): e1005921. DOI: 10.1371/journal.pgen.1005921.An P., Penugonda S., Thorball C., Bartha I., Goedert J., Donfield S., Buchbinder S., Binns-Roemer E., Kirk G., Zhang W., Fellay J., Yu X., Winkler C. Role of APOBEC3F gene variation in HIV-1 disease Progression and Pneumocystis pneumonia. PLoS Genet. 2016; 12 (3): e1005921. DOI: 10.1371/journal.pgen.1005921.Altfeld M., Kalife E.T., Qi Y., Streeck H., Lichterfeld M., Johnston M., Burgett N., Swartz M., Yang A., Alter G., Yu X., Meier A., Rockstroh J., Allen T., Jessen H., Rosenberg E., Carrington M., Walker B. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med. 2006; 3 (10): e403. DOI: 10.1371/journal.pmed.0030403.Altfeld M., Kalife E.T., Qi Y., Streeck H., Lichterfeld M., Johnston M., Burgett N., Swartz M., Yang A., Alter G., Yu X., Meier A., Rockstroh J., Allen T., Jessen H., Rosenberg E., Carrington M., Walker B. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med. 2006; 3 (10): e403. DOI: 10.1371/journal.pmed.0030403.Masemola A., Mashishi T., Khoury G., Mohube P., Mokgotho P., Vardas E., Colvin M., Zijenah L., Katzenstein D., Musonda R., Allen S., Kumwenda N., Taha T., Gray G., McIntyre J., Karim S.A., Sheppard H.W., Gray C.M. HIVNET 028 Study Team. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J. Virol. 2004; 78 (7): 3233–3243. DOI: 10.1128/JVI.78.7.3233-3243.2004.Masemola A., Mashishi T., Khoury G., Mohube P., Mokgotho P., Vardas E., Colvin M., Zijenah L., Katzenstein D., Musonda R., Allen S., Kumwenda N., Taha T., Gray G., McIntyre J., Karim S.A., Sheppard H.W., Gray C.M. HIVNET 028 Study Team. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J. Virol. 2004; 78 (7): 3233–3243. DOI: 10.1128/JVI.78.7.3233-3243.2004.Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., Rathnavalu P., Moore C., Pfafferott K.J., Hilton L., Zimbwa P., Moore S., Allen T., Brander C., Addo M., Altfeld M., James I., Mallal S., Bunce M., Barber L.D., Szinger J., Day C., Klenerman P., Mullins J., Korber B., Coovadia H.M., Walker B.D., Goulder P.J. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature. 2004; 432 (7018): 769–775. DOI: 10.1038/nature03113.Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., Rathnavalu P., Moore C., Pfafferott K.J., Hilton L., Zimbwa P., Moore S., Allen T., Brander C., Addo M., Altfeld M., James I., Mallal S., Bunce M., Barber L.D., Szinger J., Day C., Klenerman P., Mullins J., Korber B., Coovadia H.M., Walker B.D., Goulder P.J. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature. 2004; 432 (7018): 769–775. DOI: 10.1038/nature03113.Gao X., Bashirova A., Iversen A., Phair J., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., Altfeld M., O’Brien S., Carrington M. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat. Med. 2005; 11 (12): 1290–1292. DOI: 10.1038/nm1333.Gao X., Bashirova A., Iversen A., Phair J., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., Altfeld M., O’Brien S., Carrington M. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat. Med. 2005; 11 (12): 1290–1292. DOI: 10.1038/nm1333.Gillespie G., Kaul R., Dong T., Yang H., Rostron T., Bwayo J., Kiama P., Peto T., Plummer F., McMichael A., Rowland-Jones S. Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS. 2002; 16 (7): 961–972. DOI: 10.1097/00002030-200205030-00002.Gillespie G., Kaul R., Dong T., Yang H., Rostron T., Bwayo J., Kiama P., Peto T., Plummer F., McMichael A., Rowland-Jones S. Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS. 2002; 16 (7): 961–972. DOI: 10.1097/00002030-200205030-00002.Miura T., Brockman M.A., Schneidewind A., Lobritz M., Pereyra F., Rathod A., Block B.L., Brumme Z.L., Brumme C.J., Baker B., Rothchild A.C., Li B., Trocha A., Cutrell E., Frahm N., Brander C., Toth I., Arts E.J., Allen T.M., Walker B.D. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. J. Virol. 2009; 83 (6): 2743–2755. DOI: 10.1128/JVI.02265-08.Miura T., Brockman M.A., Schneidewind A., Lobritz M., Pereyra F., Rathod A., Block B.L., Brumme Z.L., Brumme C.J., Baker B., Rothchild A.C., Li B., Trocha A., Cutrell E., Frahm N., Brander C., Toth I., Arts E.J., Allen T.M., Walker B.D. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. J. Virol. 2009; 83 (6): 2743–2755. DOI: 10.1128/JVI.02265-08.Kaur G., Mehra N. Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes. Tissue Antigens. 2009; 74 (5): 373–385. DOI: 10.1111/j.1399-0039.2009.01337.x.Kaur G., Mehra N. Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes. Tissue Antigens. 2009; 74 (5): 373–385. DOI: 10.1111/j.1399-0039.2009.01337.x.Bailey J., Williams T., Siliciano R., Blankson J. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J. Exp. Med. 2006; 203 (5): 1357–1369. DOI: 10.1084/jem.20052319.Bailey J., Williams T., Siliciano R., Blankson J. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J. Exp. Med. 2006; 203 (5): 1357–1369. DOI: 10.1084/jem.20052319.Van Manen D., van Wout A., Schuitemaker H. Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics. Retrovirology. 2012; 9: 70. DOI: 10.1186/1742-4690-9-70.Van Manen D., van Wout A., Schuitemaker H. Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics. Retrovirology. 2012; 9: 70. DOI: 10.1186/1742-4690-9-70.Hewitt R. Abacavir Hypersensitivity Reaction. Clin. Infect. Dis. 2002; 34 (8): 1137–1142. DOI: 10.1086/339751.Hewitt R. Abacavir Hypersensitivity Reaction. Clin. Infect. Dis. 2002; 34 (8): 1137–1142. DOI: 10.1086/339751.Colombo S., Rauch A., Rotger M., Fellay J., Martinez R., Fux C., Thurnheer C., Günthard H.F., Goldstein D.B., Furrer H., Telenti A. Swiss HIV Cohort Study. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J. Infect. Dis. 2008; 198 (6): 864–867. DOI: 10.1086/591184.Colombo S., Rauch A., Rotger M., Fellay J., Martinez R., Fux C., Thurnheer C., Günthard H.F., Goldstein D.B., Furrer H., Telenti A. Swiss HIV Cohort Study. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J. Infect. Dis. 2008; 198 (6): 864–867. DOI: 10.1086/591184.Chessman D., Kostenko L., Lethborg T., Purcell A.W., Williamson N., Chen Z., Kjer-Nielsen L., Mifsud N., Tait B., Holdsworth R., Almeida C., Nolan D., Macdonald W., Archbold J., Kellerher A., Marriott D., Mallal S., Bharadwaj M., Rossjohn J., McCluskey J. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008; 28 (6): 822–832. DOI: 10.1016/j.immuni.2008.04.020.Chessman D., Kostenko L., Lethborg T., Purcell A.W., Williamson N., Chen Z., Kjer-Nielsen L., Mifsud N., Tait B., Holdsworth R., Almeida C., Nolan D., Macdonald W., Archbold J., Kellerher A., Marriott D., Mallal S., Bharadwaj M., Rossjohn J., McCluskey J. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008; 28 (6): 822–832. DOI: 10.1016/j.immuni.2008.04.020.Mallal S., Nolan D., Witt C., Masel G., Martin A., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., James I., Christiansen F. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002; 359 (9308): 727–732. DOI: 10.1016/S0140-6736(02)07873-X.Mallal S., Nolan D., Witt C., Masel G., Martin A., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., James I., Christiansen F. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002; 359 (9308): 727–732. DOI: 10.1016/S0140-6736(02)07873-X.Martin A., Nolan D., Gaudieri S., Almeida C.A., Nolan R., James I., Carvalho F., Phillips E., Christiansen F., Purcell A., McCluskey J., Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. USA. 2004; 101 (12): 4180–4185. DOI: 10.1073/pnas.0307067101.Martin A., Nolan D., Gaudieri S., Almeida C.A., Nolan R., James I., Carvalho F., Phillips E., Christiansen F., Purcell A., McCluskey J., Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. USA. 2004; 101 (12): 4180–4185. DOI: 10.1073/pnas.0307067101.Rauch A., Nolan D., Thurnheer C., Fux C., Cavassini M., Chave J., Opravil M., Phillips E., Mallal S., Furrer H.; Swiss HIV Cohort Study. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir. Ther. 2008; 13 (8): 1019–1028. DOI: 10.1086/504874.Rauch A., Nolan D., Thurnheer C., Fux C., Cavassini M., Chave J., Opravil M., Phillips E., Mallal S., Furrer H.; Swiss HIV Cohort Study. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir. Ther. 2008; 13 (8): 1019–1028. DOI: 10.1086/504874.Mahungu T., Johnson M., Owen A., Back D. The impact of pharmacogenetics on HIV therapy. Int. J. STD AIDS. 2009; 20 (3): 145–151. DOI: 10.1258/ijsa.2008.008369.Mahungu T., Johnson M., Owen A., Back D. The impact of pharmacogenetics on HIV therapy. Int. J. STD AIDS. 2009; 20 (3): 145–151. DOI: 10.1258/ijsa.2008.008369.Schneidewind A., Brockman M., Yang R., Adam R., Li B., Le Gall S., Rinaldo C., Craggs S., Allgaier R., Power K., Kuntzen T., Tung C., LaBute M., Mueller S., Harrer T., McMichael A., Goulder P., Aiken C., Brander C., Kelleher A., Allen T. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 2007; 81 (22): 12382–12393. DOI: 10.1128/JVI.01543-07.Schneidewind A., Brockman M., Yang R., Adam R., Li B., Le Gall S., Rinaldo C., Craggs S., Allgaier R., Power K., Kuntzen T., Tung C., LaBute M., Mueller S., Harrer T., McMichael A., Goulder P., Aiken C., Brander C., Kelleher A., Allen T. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 2007; 81 (22): 12382–12393. DOI: 10.1128/JVI.01543-07.Cornelissen M., Hoogland F., Back N., Jurriaans S., Zorgdrager F., Bakker M., Brinkman K., Prins M., van der Kuyl A. Multiple transmissions of a stable human leucocyte antigen-B27 cytotoxic T-cell-escape strain of HIV- 1 in The Netherlands. AIDS. 2009; 23 (12): 1495–1500. DOI: 10.1097/QAD.0b013e32832d9267.Cornelissen M., Hoogland F., Back N., Jurriaans S., Zorgdrager F., Bakker M., Brinkman K., Prins M., van der Kuyl A. Multiple transmissions of a stable human leucocyte antigen-B27 cytotoxic T-cell-escape strain of HIV- 1 in The Netherlands. AIDS. 2009; 23 (12): 1495–1500. DOI: 10.1097/QAD.0b013e32832d9267.Stephens H. HIV-1 diversity versus HLA class I polymorphism. Trends Immunol. 2005; 26 (1): 41–47. DOI: 10.1016/j.it.2004.11.001.Stephens H. HIV-1 diversity versus HLA class I polymorphism. Trends Immunol. 2005; 26 (1): 41–47. DOI: 10.1016/j.it.2004.11.001.Lajoie J., Hargrove J., Zijenah L., Humphrey J., Ward B., Roger M. Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J. Infect. Dis. 2006; 193 (2): 298–301. DOI: 10.1086/498877.Lajoie J., Hargrove J., Zijenah L., Humphrey J., Ward B., Roger M. Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J. Infect. Dis. 2006; 193 (2): 298–301. DOI: 10.1086/498877.McDonald K., Fowke K., Kimani J., Dunand V., Nagelkerke N., Ball T., Oyugi J., Njagi E., Gaur L., Brunham R., Wade J., Luscher M., Krausa P., Rowland-Jones S., Ngugi E., Bwayo J., Plummer F. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 2000; 181 (5): 1581–1589. DOI: 10.1086/315472.McDonald K., Fowke K., Kimani J., Dunand V., Nagelkerke N., Ball T., Oyugi J., Njagi E., Gaur L., Brunham R., Wade J., Luscher M., Krausa P., Rowland-Jones S., Ngugi E., Bwayo J., Plummer F. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 2000; 181 (5): 1581–1589. DOI: 10.1086/315472.Liu C., Carrington M., Kaslow R., Gao X., Rinaldo C., Jacobson L., Margolick J., Phair J., O’Brien S., Detels R. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 2003; 187 (9): 1404–1410. DOI: 10.1086/374394.Liu C., Carrington M., Kaslow R., Gao X., Rinaldo C., Jacobson L., Margolick J., Phair J., O’Brien S., Detels R. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 2003; 187 (9): 1404–1410. DOI: 10.1086/374394.Flores-Villanueva P., Hendel H., Caillat-Zucman S., Rappaport J., Burgos-Tiburcio A., Bertin-Maghit S., Ruiz-Morales J., Teran M., Rodriguez-Tafur J., Zagury J. Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J. Immunol. 2003; 170 (4): 1925–1929. DOI: 10.4049/jimmunol.170.4.1925.Flores-Villanueva P., Hendel H., Caillat-Zucman S., Rappaport J., Burgos-Tiburcio A., Bertin-Maghit S., Ruiz-Morales J., Teran M., Rodriguez-Tafur J., Zagury J. Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J. Immunol. 2003; 170 (4): 1925–1929. DOI: 10.4049/jimmunol.170.4.1925.Singh P., Kaur G., Sharma G., Mehra N. Immunogenetic basis of HIV-1 infection, transmission and disease progression. Vaccine. 2008; 26 (24): 2966–2980. DOI: 10.1016/j.vaccine.2008.01.012.Singh P., Kaur G., Sharma G., Mehra N. Immunogenetic basis of HIV-1 infection, transmission and disease progression. Vaccine. 2008; 26 (24): 2966–2980. DOI: 10.1016/j.vaccine.2008.01.012.Adnan S., Balamurugan A., Trocha A., Bennett M., Ng H., Ali A., Brander C., Yang O. Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood. 2006; 108 (10): 3414–3419. DOI: 10.1182/blood-2006-06-030668.Adnan S., Balamurugan A., Trocha A., Bennett M., Ng H., Ali A., Brander C., Yang O. Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood. 2006; 108 (10): 3414–3419. DOI: 10.1182/blood-2006-06-030668.Trachtenberg E., Korber B., Sollars C., Kepler T., Hraber P., Hayes E., Funkhouser R., Fugate M., Theiler J., Hsu Y., Kunstman K., Wu S., Phair J., Erlich H., Wolinsky S. Advantage of rare HLA supertype in HIV disease progression. Nat. Med. 2003; 9 (7): 928–935. DOI: 10.1038/nm893.Trachtenberg E., Korber B., Sollars C., Kepler T., Hraber P., Hayes E., Funkhouser R., Fugate M., Theiler J., Hsu Y., Kunstman K., Wu S., Phair J., Erlich H., Wolinsky S. Advantage of rare HLA supertype in HIV disease progression. Nat. Med. 2003; 9 (7): 928–935. DOI: 10.1038/nm893.HIV molecular immunology database. 2016. http://www.hiv.lanl.gov/content/immunology/.HIV molecular immunology database. 2016. http://www.hiv.lanl.gov/content/immunology/.Lacap P., Huntington J., Luo M., Nagelkerke N., Bielawny T., Kimani J., Wachihi C., Ngugi E., Plummer F. Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. AIDS. 2008; 22 (9): 1029–1038. DOI: 10.1097/QAD.0b013e3282ffb3db.Lacap P., Huntington J., Luo M., Nagelkerke N., Bielawny T., Kimani J., Wachihi C., Ngugi E., Plummer F. Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. AIDS. 2008; 22 (9): 1029–1038. DOI: 10.1097/QAD.0b013e3282ffb3db.An P., Winkler C. Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet. 2010; 26 (3): 119–131. DOI: 10.1016/j.tig.2010.01.002.An P., Winkler C. Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet. 2010; 26 (3): 119–131. DOI: 10.1016/j.tig.2010.01.002.Malhotra U., Holte S., Dutta S., Berrey M., Delpit E., Koelle D., Sette A., Corey L., McElrath M. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J. Clin. Invest. 2001; 107 (4): 505–517. DOI: 10.1172/JCI11275.Malhotra U., Holte S., Dutta S., Berrey M., Delpit E., Koelle D., Sette A., Corey L., McElrath M. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J. Clin. Invest. 2001; 107 (4): 505–517. DOI: 10.1172/JCI11275.Hardie R., Luo M., Bruneau B., Knight E., Nagelkerke N., Kimani J., Wachihi C., Ngugi E., Plummer F. Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS. 2008; 22 (7): 807–816. DOI: 10.1097/QAD.0b013e3282f51b71.Hardie R., Luo M., Bruneau B., Knight E., Nagelkerke N., Kimani J., Wachihi C., Ngugi E., Plummer F. Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS. 2008; 22 (7): 807–816. DOI: 10.1097/QAD.0b013e3282f51b71.Carrington M., Martin M., van Bergen J. KIR-HLA intercourse in HIV disease. Trends Microbiol. 2008; 16 (12): 620–627. DOI: 10.1016/j.tim.2008.09.002Carrington M., Martin M., van Bergen J. KIR-HLA intercourse in HIV disease. Trends Microbiol. 2008; 16 (12): 620–627. DOI: 10.1016/j.tim.2008.09.002Boyton R., Altmann D. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin. Exp. Immunol. 2007; 149 (1): 1–8. DOI: 10.1111/j.1365-2249.2007.03424.x.Boyton R., Altmann D. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin. Exp. Immunol. 2007; 149 (1): 1–8. DOI: 10.1111/j.1365-2249.2007.03424.x.Jennes W., Verheyden S., Demanet C., Adjé-Touré C., Vuylsteke B., Nkengasong J., Kestens L. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J. Immunol. 2006; 177 (10): 6588– 6592. DOI: 10.4049/jimmunol.177.10.6588.Jennes W., Verheyden S., Demanet C., Adjé-Touré C., Vuylsteke B., Nkengasong J., Kestens L. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J. Immunol. 2006; 177 (10): 6588– 6592. DOI: 10.4049/jimmunol.177.10.6588.Qi Y., Martin M., Gao X., Jacobson L., Goedert J., Buchbinder S., Kirk G., O’Brien S., Trowsdale J., Carrington M. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2006; 2 (8): e79. DOI: 10.1371/journal.ppat.0020079.Qi Y., Martin M., Gao X., Jacobson L., Goedert J., Buchbinder S., Kirk G., O’Brien S., Trowsdale J., Carrington M. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2006; 2 (8): e79. DOI: 10.1371/journal.ppat.0020079.Long B., Ndhlovu L., Oksenberg J., Lanier L., Hecht F., Nixon D., Barbour J. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J. Virol. 2008; 82 (10): 4785–4792. DOI: 10.1128/JVI.02449-07.Long B., Ndhlovu L., Oksenberg J., Lanier L., Hecht F., Nixon D., Barbour J. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J. Virol. 2008; 82 (10): 4785–4792. DOI: 10.1128/JVI.02449-07.Alter G., Martin M., Teigen N., Carr W., Suscovich T., Schneidewind A., Streeck H., Waring M., Meier A., Brander C., Lifson J., Allen T., Carrington M., Altfeld M. Differential natural killer cell mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 2007; 204 (12): 3027–3036. DOI: 10.1084/jem.20070695.Alter G., Martin M., Teigen N., Carr W., Suscovich T., Schneidewind A., Streeck H., Waring M., Meier A., Brander C., Lifson J., Allen T., Carrington M., Altfeld M. Differential natural killer cell mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 2007; 204 (12): 3027–3036. DOI: 10.1084/jem.20070695.Boulet S., Kleyman M., Kim J., Kamya P., Sharafi S., Simic N., Bruneau J., Routy J., Tsoukas C., Bernard N. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS. 2008; 22 (12): 1487–1491. DOI: 10.1097/QAD.0b013e3282ffde7e.Boulet S., Kleyman M., Kim J., Kamya P., Sharafi S., Simic N., Bruneau J., Routy J., Tsoukas C., Bernard N. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS. 2008; 22 (12): 1487–1491. DOI: 10.1097/QAD.0b013e3282ffde7e.Habegger de Sorrentino A., Sinchi J.L., Marinic K., Lуpez R., Illiovich E. Kir-HLA-A and B alleles of the Bw4 epitope against HIV infection in discordant heterosexual couples in Chaco Argentina. Immunology. 2013; 140 (2): 273–279. DOI: 10.1111/imm.12137.Habegger de Sorrentino A., Sinchi J.L., Marinic K., Lуpez R., Illiovich E. Kir-HLA-A and B alleles of the Bw4 epitope against HIV infection in discordant heterosexual couples in Chaco Argentina. Immunology. 2013; 140 (2): 273–279. DOI: 10.1111/imm.12137.Lin Y., Lan Y., Hung C., Lin T., Huang S., Liao C., Lin C., Lai C., Tien N., Liu X., Ho M., Chien W., Chen J., Wang J., Tsai F. Variants in ZNRD1 gene predict HIV-1/AIDS disease progression in a Han Chinese population in Taiwan. PLoS One. 2013; 8 (7): e67572. DOI: 10.1371/journal.pone.0067572.Lin Y., Lan Y., Hung C., Lin T., Huang S., Liao C., Lin C., Lai C., Tien N., Liu X., Ho M., Chien W., Chen J., Wang J., Tsai F. Variants in ZNRD1 gene predict HIV-1/AIDS disease progression in a Han Chinese population in Taiwan. PLoS One. 2013; 8 (7): e67572. DOI: 10.1371/journal.pone.0067572.Ballana E., Senserrich J., Pauls E., Faner R., Mercader J. ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression. Clin. Infect. Dis. 2010; 50 (7): 1022–1032. DOI: 10.1086/651114.Ballana E., Senserrich J., Pauls E., Faner R., Mercader J. ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression. Clin. Infect. Dis. 2010; 50 (7): 1022–1032. DOI: 10.1086/651114.

The authors declare that there are no conflicts of interest present.